ArticleLeukemia2020
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.
Abstract read
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.Haematologica · 2024Trial
- Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma.Targeted oncology · 2026Review
- Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.Blood advances · 2025Article
- RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.World journal of surgical oncology · 2025Article
- Landscapes of immunoglobulin heavy-chain gene repertoire and its cytogenetic abnormalities in Chinese patients with multiple myeloma.Scientific reports · 2025Article
- Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.Leukemia · 2024Article
- Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Longitudinal genetically detectable minimal residual disease by fluorescenceTherapeutic advances in medical oncology · 2024Article
- Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.Annals of hematology · 2023Article
- Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myeloma.Cancer pathogenesis and therapy · 2023Article
- Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.Cancer biology & medicine · 2023Article
- Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.Blood advances · 2022Article
- Minimal residual disease in multiple myeloma: current status.Biomarker research · 2021Review
- [Progress in clonal evolution of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.International journal of hematology · 2021Article
- Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.Leukemia · 2021Article
- Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma.Cancers · 2021Review
- Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Gang An *State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China. angang@ihcams.ac.cn.
Yuting Yan *State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Yan XuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Xuehan MaoState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Jiahui LiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Huishou FanState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Qi WangState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Chenxing DuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Zengjun LiState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Shuhua YiState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Rui LvState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Shuhui DengState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Weiwei SuiState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Mingwei FuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Mu HaoState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Wenyang HuangState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Dehui ZouState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Yaozhong ZhaoState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Chenglu YuanQilu Hospital of Shandong University (Qingdao), Qingdao, China.
Xin DuShenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Jianxiang WangState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.
Tao ChengState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China.ORCID http://orcid.org/0000-0003-4395-1095
Yu-Tzu TaiLeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nikhil C MunshiLeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. nikhil_munshi@dfci.harvard.edu.
Lugui QiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 300020, Tianjin, China. qiulg@ihcams.ac.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent attempts have focused on identifying fewer magnitude of minimal residual disease (MRD) rather than exploring the biological and genetic features of the residual plasma cells (PCs). Here, a cohort of 193 patients with at least one cytogenetic abnormalities (CA) at diagnosis were analyzed, and interphase fluorescence in situ hybridization (iFISH) analyses were performed in patient-paired diagnostic and posttherapy samples. Persistent CA in residual PCs were observed for the majority of patients (63%), even detectable in 28/63 (44%) patients with MRD negativity (<10
Indexed as
AdultAgedAged, 80 and overClinical Trials as TopicCytogeneticsFemaleHumansIn Situ Hybridization, FluorescenceLongitudinal StudiesMaleMiddle AgedMultiple MyelomaNeoplasm, ResidualPlasma CellsProspective Studies
Identifiers
PMID
31591469What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.